Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387781 | 1.00 | RAB9A (0.64) | RAB9AHPGDGRM5SMN1; SMN2MEN1 | |
| SCHEMBL3387787 | 1.00 | RAB9A (0.64) | RAB9AHPGDGRM5SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL30585970 | 0.84 | RAB9A (0.57) | RAB9AHPGDGRM5SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL21640813 | 0.84 | RAB9A (0.57) | RAB9AHPGDGRM5SMN1; SMN2MEN1 | |
| SCHEMBL18549447 | 0.78 | RAB9A (0.57) | RAB9AHPGDGRM5SMN1; SMN2MEN1 | |
| SCHEMBL18549446 | 0.78 | RAB9A (0.57) | RAB9AHPGDGRM5SMN1; SMN2MEN1 | |
| SCHEMBL31725239 | 0.78 | RAB9A (0.78) | RAB9AGRM5SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14353530 | 0.78 | RAB9A (1.00) | RAB9AGRM5SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3119185 | 0.78 | RAB9A (0.78) | RAB9AGRM5SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21222380 | 0.78 | SMN1; SMN2 (0.57) | RAB9AHPGDSMN1; SMN2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716472-B2 | Tripodal cyclohexane derivatives and their use as carbohydrate receptors | UNIVERSITY OF ROCHESTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2010-02-18 | — | — | US | disclosed |
| WO-2008048967-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | UNIVERSITY OF ROCHESTER (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041568-A1 | TRIPODAL CYCLOHEXANE DERIVATIVES AND THEIR USE AS CARBOHYDRATE RECEPTORS | CA14, HCAR1, CCKAR | RAB9A 4661/4885HPGD 3154/4885GRM5 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.